Illumina (ILMN) opened 2026 with Q1 revenue of US$1,091 million and basic EPS of US$0.88, setting the tone for how the year is starting to shape up after its recent return to profitability. Over the past five quarters, revenue has moved within a tight band between US$1,041 million and US$1,159 million, while quarterly basic EPS has ranged from US$0.82 to US$2.18. This gives investors a clearer view of how earnings power has translated from the top line. With trailing 12 month net income back in positive territory and EPS supported by both underlying operations and a prior one off gain, the latest quarter highlights margins as a key focus for anyone tracking the story from here.

See our full analysis for Illumina.

With the headline numbers on the table, the next step is to see how these results line up with the widely followed narratives around Illumina's growth, profitability, and risk profile, and where the fresh data starts to challenge those stories.

Profitability Back, But One Off Gain Matters

• On a trailing 12 month basis, Illumina recorded net income of US$853 million and basic EPS of US$5.56, with that period including a US$266 million one off gain that has a material impact on reported profitability.
• Bulls point to Illumina becoming profitable over the last year and 3.9% annual earnings growth over five years as evidence of a durable earnings story. However, the size of the US$266 million one off gain means investors need to separate:
  • The recurring profit picture seen in quarterly net income between US$131 million and US$334 million over the last five reported quarters.
  • The boosted trailing EPS and margins that are influenced by that single gain rather than day to day operations.

On this view, bulls are confident the recent return to profit can support future compounding, but the trailing figures also ask you to judge how much of that is repeatable and how much is accounting uplift from the one off item. 🐂 Illumina Bull Case

P/E Discount Versus Peers And DCF Fair Value

• Illumina trades on a trailing P/E of 24.2x compared with a peer average of 33.8x and a Global Life Sciences average of 34.8x, while the current share price of US$135.78 sits about 14.7% below the stated DCF fair value of US$159.26.
• Consensus narrative highlights that analysts as a group have a price target of US$138.94, and the numbers here create an interesting tension between valuation signals:
  • The lower P/E than peers and industry, alongside the DCF fair value being above the current price, points to a valuation gap if earnings and cash flows track the assumptions used in those models.
  • At the same time, the consensus price target is only slightly above the current share price, which suggests analysts are treating the P/E discount and DCF output cautiously given the one off boost to trailing earnings.

Forecast Growth Versus Bear Concerns

• Forecasts in the data point to revenue growth of about 5.7% per year and earnings growth of roughly 8.9% per year, both described as below cited US market averages but still higher than the 3.9% annual earnings growth seen over the past five years.
• Bears focus on rising competition, regulatory pressures and slower research spending as reasons growth could be under pressure, and the figures here partly echo and partly challenge that view:
  • The mid single digit revenue growth forecast lines up with the idea that growth may be steady rather than rapid, which fits with concerns about funding constraints and a more competitive market for instruments and consumables.
  • However, the higher forecast earnings growth rate versus the 5 year 3.9% track record suggests expectations for margin resilience or efficiency gains that sit against the bearish argument that cost pressures will fully erode profitability.

Skeptics point to these mid single digit growth forecasts as evidence that upside is limited if competitive and regulatory risks bite, while the projected step up in earnings growth keeps open the possibility that Illumina can defend margins better than the bearish narrative suggests. 🐻 Illumina Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Illumina on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, sentiment on Illumina is clearly mixed. It makes sense to look at the underlying data yourself and move quickly to shape your own view with the help of 3 key rewards and 1 important warning sign

See What Else Is Out There

Illumina's use of a US$266 million one off gain, mid single digit growth forecasts, and P/E discount versus peers all raise questions about how durable its earnings story really is.

If you want ideas where pricing looks more straightforward and less tied to special items, check out the 51 high quality undervalued stocks to quickly compare companies with potential valuation gaps against your expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.